Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases.

Journal: Scientific reports
Published Date:

Abstract

Hepatocellular carcinoma (HCC) is a common malignant tumor in China. In the present study, we aimed to construct and verify a prediction model of recurrence in HCC patients using databases (TCGA, AMC and Inserm) and machine learning methods and obtain the gene signature that could predict early relapse of HCC. Statistical methods, such as feature selection, survival analysis and Chi-Square test in R software, were used to analyze and select mutant genes related to disease free survival (DFS), race and vascular invasion. In addition, whole-exome sequencing was performed on 10 HCC patients recruited from our center, and the sequencing results were compared with the databases. Using the databases and machine learning methods, the prediction model of recurrence was constructed and optimized, and the selected mutant genes were verified in the test group. The accuracy of prediction was 74.19%. Moreover, these 10 patients from our center were used to verify these mutant genes and the prediction model, and a success rate of 80% was achieved. Collectively, we discovered recurrence-related genes and established recurrence prediction model of recurrence for HCC patients, which could provide significant guidance for clinical prediction of recurrence.

Authors

  • Jie Shen
    Anhui Provincial Center for Drug Clinical Evaluation, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui 241001, China; Pharmacy School, Wannan Medical College, Wuhu, Anhui 241002, China; Department of Clinical Pharmacy, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui 241001, China; Anhui Provincial Engineering Research Center for Polysaccharides Drugs, Wannan Medical College, Wuhu, Anhui 241001, China.
  • Liang Qi
    Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Zhengyun Zou
    Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, 210008, Jiangsu Province, China.
  • Juan Du
    Department of Hygiene Detection Center, School of Public Health, Southern Medical University (Guangdong Provincial Key Laboratory of Tropical Disease Research), Guangzhou, Guangdong, China.
  • Weiwei Kong
    Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, 210008, Jiangsu Province, China.
  • Lianjun Zhao
    Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, 210008, Jiangsu Province, China.
  • Jia Wei
    Department of Thyroid Surgery, The First Hospital of Jilin University Changchun 130021 P. R. China mengxiany@mail.jlu.edu.cn.
  • Ling Lin
    Center for Sleep Science and Medicine, Stanford University, Stanford, 94304, CA, USA.
  • Min Ren
    Tianjin Cardiovascular Institute, Tianjin Chest Hospital, Tianjin, China.
  • Baorui Liu
    Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, 210008, Jiangsu Province, China. baoruiliu@nju.edu.cn.